Drug allergy in primary care: systematic review to support quality of management and optimization of healthcare pathways

Gaudin, Clara; Mamodaly, Myriam; Kocks, Janwillem; Velde, Jantina van der; Blok, Bertine De Flokstra; Angier, Elisabeth; Gawlik, Radek; Démoly, P.; Tanno, Luciana Kase

doi:10.1016/j.waojou.2020.100394

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These changes may relate to availability, costs and prescription habits. Fluoroquinolones, which cause mast cell degranulation through MRGPRX2, are the most common non‐BL antibiotic involved in DA in Spain, 129 Italy, 32 Vietnam 47 and China 49 and drug‐induced anaphylaxis in the USA 15 due to moxifloxacin 31,129–131 . Ciprofloxacin has been associated with an increased risk for SCARs 131 .…”

Section: Prevalence and Risk Factors Of Da: Specific Drugsmentioning

confidence: 99%

“…10 Mortality and hospital admission data underestimates the true rate of DA since most reactions occur outside the hospital settings and a minority of reactions result in hospitalization. [11][12][13][14] It is estimated that DA accounts for 1%-2% of hospital admissions [15][16][17][18][19] and 14% of emergency department visits of which 0.6% are drug-induced anaphylaxis and lead to hospitalizations in 15% of cases. 20 The prevalence of self-reported DA is higher in adults, increases with age 21,22 and more adults than children are hospitalized due to DA.…”

Section: Drug Allergy Documentation Prevalence and World Differencesmentioning

confidence: 99%

See 1 more Smart Citation

Changing patterns in the epidemiology of drug allergy

Doña,

Torres,

Celik

et al. 2023

Allergy

View full text Add to dashboard Cite

Drug allergy (DA) remains a complex and unaddressed problem worldwide that often deprives patients of optimal medication choices and places them at risk for life‐threatening reactions. Underdiagnosis and overdiagnosis are common and due to the lack of standardized definitions and biomarkers. The true burden of DA is unknown, and recent efforts in data gathering through electronic medical records are starting to provide emerging patterns around the world. Ten percent of the general population engaged in health care claim to have a DA, and the most common label is penicillin allergy. Up to 20% of emergency room visits for anaphylaxis are due to DA and 15%–20% of hospitalized patients report DA. It is estimated that DA will increase based on the availability and use of new and targeted antibiotics, vaccines, chemotherapies, biologicals, and small molecules, which are aimed at improving patient's options and quality of life. Global and regional variations in the prevalence of diseases such as human immunodeficiency virus and mycobacterial diseases, and the drugs used to treat these infections have an impact on DA. The aim of this review is to provide an update on the global impact of DA by presenting emerging data on drug epidemiology in adult and pediatric populations.

show abstract

Section: Prevalence and Risk Factors Of Da: Specific Drugsmentioning

confidence: 99%

Section: Drug Allergy Documentation Prevalence and World Differencesmentioning

confidence: 99%

Changing patterns in the epidemiology of drug allergy

Doña,

Torres,

Celik

et al. 2023

Allergy

View full text Add to dashboard Cite

show abstract

“…All medications and pharmacological agents can potentially cause adverse drug reactions (ADRs). The classification proposed by Rawlins and Thompson [1,2 ▪ ] has been recently reviewed and simplified, and came up with the standards as follows: ADRs are divided into two categories: type A reactions (predictable, common and dose-dependent, such as drug toxicity and pharmacological side effects) and type B reactions (unpredictable, less common and not dose-dependent, and mostly individual related, representing the sub-set of hypersensitivity and allergic reactions). Drug hypersensitivity reactions (DHRs) are defined as the adverse reactions of pharmaceutical formulations that clinically resemble allergy, and can be immunologically mediated (allergic) or nonimmunologically mediated (nonallergic) [1] (Fig.…”

Section: Introductionmentioning

confidence: 99%

Drug allergy awareness and perspectives with the implementation of the International Classification of Diseases-11

Tanno,

Briand,

Perie

et al. 2024

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of review To understand the current global scale of drug hypersensitivity (DH) and drug allergy (DA), and to identify possible strategies to increase the accuracy of epidemiological data. Recent findings Global patterns of DH/DA seem to be changing and increasing worldwide, but there are still great challenges in capturing quality DH/DA mortality and morbidity statistics (MMS). DH/DA MMS may gain new perspectives with the global implementation of the International Classification of Diseases (ICD)-11. Improving the quality of epidemiological data related to DH/DA should clarify areas of uncertainty, which would lead to better strategies to reduce the burden of these conditions. Summary DH/DA remains a complex and unaddressed problem globally that often deprives patients of optimal medication choices and places them at risk for life-threatening reactions. DH/DA labels should contribute to people well being, by protecting true allergic individuals from being re-exposed to their allergic drugs and providing needed medications to individuals wrongly labeled as allergic or who have lost allergic sensitivity. The true rate of DH/DA is in fact unknown due to a number of factors, such as misdiagnosis, miscoding and under- and over-notification, among others. Moreover, there is lack of data about DH/DA epidemiology in many countries. Difficulties on collecting accurate and comparable data should be acknowledged, with great impact in the correct labeling DH/DA in electronic health records and official statistics. More accurate definitions, classification and coding may contribute to a better-quality MMS thanks to the ICD-11, under implementation worldwide. Improving the quality of epidemiological data related to DH/DA should clarify areas of uncertainty, which would lead to better strategies to reduce the burden of these conditions. As knowledge derived from populations is key information for more realistic decision-making, the construction of the new section addressed to DH/DA in the ICD-11 will allow the collection of more accurate epidemiological data to support quality management of patients, and facilitate healthcare planning to implement public health measures to prevent and reduce the morbidity and mortality attributable to these conditions.

show abstract

Drug allergy in primary care: systematic review to support quality of management and optimization of healthcare pathways

Cited by 2 publications

References 0 publications

Changing patterns in the epidemiology of drug allergy

Changing patterns in the epidemiology of drug allergy

Drug allergy awareness and perspectives with the implementation of the International Classification of Diseases-11

Contact Info

Product

Resources

About